Academic Journal of Medical Sciences
Published July 21, 2022 | Version Citation: Taha J. A., Sinjari H. Y. Cardiovascular Disease Risk Assessment in Kidney Transplant Recipients. Academic Journal of Medical Sciences, 2022, 8(3): 199-208
Journal article Open

Cardiovascular Disease Risk Assessment in Kidney Transplant Recipients

Authors/Creators

  • 1. Hawler Teaching hospital, Erbil, Iraq
  • 2. Department of medicine, Hawler Medical University, Erbil, Iraq

Contributors

  • 1. Hawler Teaching hospital, Erbil, Iraq
  • 2. Department of medicine, Hawler Medical University, Erbil, Iraq

Description

Cardiovascular Disease Risk Assessment in Kidney Transplant Recipients

Background: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in kidney transplant recipients (KTR). Risk factors for CVD are prevalent pre- and post-transplantation.
Objective: To identify CVD and to examine related risk factors after six months of kidney transplantation.
Methods: A cross sectional study was conducted in the nephrology unit, Hawler teaching hospital, Erbil, Iraq, from 1st July 2021 to 30th December 2021 on a sample of KTR after six months of transplantation. Recipients’ characteristics including; age, gender, body mass index, history of rejection, prior CVD, smoking, hypertension, and diabetes mellitus were recorded. Lab tests were done; serum creatinine, 25(OH) D, C-reactive protein (CRP), parathyroid hormone (PTH), lipid profile, hemoglobin, HBA1C, and urinary protein. The CKD-EPI equation was used to estimate glomerular filtration rate (eGFR). In addition to history and physical exam, diagnosis of cardiac abnormalities were accomplished through electrocardiography and echocardiography studies.
Results: A total of 100 KTR were studied, of them 52% were male, their mean age was 43.8 ± 10.9 years. CVD was detected in 18% of participants, associated with multiple risk factors; older age, previous CVD, smoking, history of rejection, eGFR< 60mL/min/1.73m2, anemia, and proteinuria, all with a highly significant p value (<0.001), left ventricular hypertrophy (LVH) (p 0.02), hypertension (p 0.01), high CRP (p 0.01), and HbA1C > 7% (p 0.03). Gender, obesity, LDL cholesterol, triglyceride, vitamin D, and high PTH were not significantly related to CVD in KTR.
Conclusion: Cardiovascular diseases are common among KTR, it were significantly associated with increasing age, prior CVD, smoking, history of rejection, low eGFR, hypertension, anemia, high HbA1C, proteinuria, high CRP and LVH.    

Notes

Citation: Taha J. A., Sinjari H. Y. Cardiovascular Disease Risk Assessment in Kidney Transplant Recipients. Academic Journal of Medical Sciences, 2022, 8(3): 199-208

Files

Cardiovascular Disease Risk Assessment in Kidney Transplant Recipients.pdf

Files (1.1 MB)

Additional details

References

  • 1. Rose C, Gill J, Gill JS. Association of kidney transplantation with survival in patients with long dialysis exposure. Clinical Journal of the American Society of Nephrology. 2017;12(12):2024-31.
  • 2. Seoane-Pillado MT, Pita-Fernández S, Valdés-Cañedo F, Seijo-Bestilleiro R, Pértega-Díaz S, Fernández-Rivera C, Alonso-Hernández Á, González-Martín C, Balboa-Barreiro V. Incidence of cardiovascular events and associated risk factors in kidney transplant patients: a competing risks survival analysis. BMC Cardiovascular Disorders. 2017; 17(1):1-7
  • 3. OPTN/SRTR 2017 Annual Data report. Scientific Registry of Transplant Recipients. Available at: http://srtr. Transplant.hrsa.gov/annual _reports/Default.aspx. accessed at July 13, 2021
  • 4. Mathur AK, Chang YH, Steidley DE, Heilman R, Khurmi N, Wasif N, et al. Patterns of care and outcomes in cardiovascular disease after kidney transplantation in the United States. Transplant Direct 2017; 3 (2): e126.
  • 5. Pilmore H, Dent H, Chang S, McDonald SP, Chadban SJ. Reduction in cardiovascular death after kidney transplantation. Transplantation. 2010;89(7):851-7.
  • 6. Stoumpos S, Jardine AG, Mark PB. Cardiovascular morbidity and mortality after kidney transplantation. Transplant International. 2015; 28(1):10-21.
  • 7. Birdwell KA, Park M. Post-transplant cardiovascular disease. Clinical Journal of the American Society of Nephrology. 2021;16(12):1878-89.
  • 8. Levin A, Tonelli M, Bonventre J, Coresh J, Donner JA, Fogo AB, Fox CS, Gansevoort RT, Heerspink HJ, Jardine M, Kasiske B. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. The Lancet. 2017 Oct 21;390(10105):1888-917.
  • 9. O'Shaughnessy MM, Liu S, Montez-Rath ME, Lafayette RA, Winkelmayer WC. Cause of kidney disease and cardiovascular events in a national cohort of US patients with end-stage renal disease on dialysis: a retrospective analysis. European heart journal. 2019;40(11):887-98.
  • 10. Carpenter MA, Weir MR, Adey DB, House AA, Bostom AG, Kusek JW. Inadequacy of cardiovascular risk factor management in chronic kidney transplantation—Evidence from the FAVORIT study. Clin Transplant 2012; 26(4) : E438–E446
  • 11. House AA, Wanner C, Sarnak MJ, Piña IL, McIntyre CW, Komenda P, Kasiske BL, Deswal A, DeFilippi CR, Cleland JG, Anker SD. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney international. 2019 Jun 1;95(6):1304-17.
  • 12. Lenihan CR, Montez‐Rath ME, Scandling JD, Turakhia MP, Winkelmayer WC. Outcomes after kidney transplantation of patients previously diagnosed with atrial fibrillation. American Journal of Transplantation. 2013;13(6):1566-75
  • 13. Saran R, Robinson B, Abbott KC. US Renal Data System 2017 annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2018; 71(3):A7.
  • 14. Ali A. Renal Transplantation Data from Iraq. Transplantation 2018; 102: S509.
  • 15. Becker GJ, Wheeler DC, De Zeeuw D, Fujita T, Furth SL, Holdaas H, et al.. Kidney disease: Improving global outcomes (KDIGO) blood pressure work group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney International Supplements. 2012; 2(5):337-414.
  • 16. Delville M, Sabbah L, Girard D, Elie C, Manceau S, Piketty M, Martinez F, Méjean A, Legendre C, Sberro-Soussan R. Prevalence and predictors of early cardiovascular events after kidney transplantation: evaluation of pre-transplant cardiovascular work-up. PloS one. 2015;10(6):e0131237.
  • 17. Rangaswami J, Mathew RO, Parasuraman R, Tantisattamo E, Lubetzky M, Rao S, Yaqub MS, Birdwell KA, Bennett W, Dalal P, Kapoor R. Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies. Nephrology Dialysis Transplantation. 2019;34(5):760-73.
  • 18. Soveri I, Holme I, Holdaas H, Budde K, Jardine AG, Fellström B. A cardiovascular risk calculator for renal transplant recipients. Transplantation. 2012;94(1):57-62.
  • 19. Seoane-Pillado MT, Pita-Fernández S, Valdés-Cañedo F, Seijo-Bestilleiro R, Pértega-Díaz S, Fernández-Rivera C, Alonso-Hernández Á, González-Martín C, Balboa-Barreiro V. Incidence of cardiovascular events and associated risk factors in kidney transplant patients: a competing risks survival analysis. BMC Cardiovascular Disorders. 2017;17(1):1-7.
  • 20. Hoffman N, Prunean A, Dhillon A, Danovivitch GM, Lee MS, et al. Revised cardiac risk index (RCRI) is a useful tool for evaluation of perioperative cardiac morbidity in kidney transplant recipients. Transplantation 2013; 96(7): 639-43.
  • 21. Fujikura K, Peltzer B, Tiwari N, Shim HG, Dinhofer AB, Shitole SG, Kizer JR, Garcia MJ. Reduced global longitudinal strain is associated with increased risk of cardiovascular events or death after kidney transplant. International journal of cardiology. 2018; 272:323-8.
  • 22. Goyal A, Chatterjee K, Mathew RO, Sidhu MS, Bangalore S, McCullough PA, Rangaswami J. In-hospital mortality and major adverse cardiovascular events after kidney transplantation in the United States. Cardiorenal medicine. 2019;9(1):51-60
  • 23. El-Shahawy O, Shires DA, Elston Lafata J. Assessment of the efficiency of tobacco cessation counseling in primary care. Evaluation & the Health Professions. 2016 Sep;39(3):326-35.
  • 24. Nogueira J, Haririan A, Jacobs S, Cooper M, Weir M. Cigarette smoking, kidney function and mortality after live donor kidney transplant. Am J Kidney Dis 2010; 55: 907-915
  • 25. Devine PA, Courtney AE, Maxwell AP. Cardiovascular risk in renal transplant recipients. Journal of Nephrology. 2019 Jun;32(3):389-99.
  • 26. Wanner C, Tonelli M. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney international. 2014 Jun 1;85(6):1303-9.
  • 27. Weiner D, Carpenter M, Levey A. Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial. Am J Transplant. 2012; 12: 2437-45